ASH 2021 | CAR-T therapy in multiple myeloma: research blind spots
CAR T-cell therapy has been shown to elicit high-quality responses in patients with multiple myeloma. Positive data from the pivotal Phase II KarMMa trial led to the approval of idecabtagene vicleucel, a BCMA-directed CAR T-cell therapy, in patients with heavily pretreated relapsed/refractory myeloma, and ongoing trials are investigating the utility of CAR-T versus standard of care regimens in earlier lines of treatment. Andrew Cowan, MD, University of Washington, Seattle, WA, discusses the blind spots in myeloma CAR-T research, highlighting key topics such as treatment sequencing, combination studies, and retreatment with BCMA-targeted therapies. This interview took place at during 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
